Life
Pharmaceutical Launch Delays in Europe Linked to U.S. Pricing Policies
Drugmakers are postponing the introduction of new medications in Europe, influenced by changes in U.S. pricing policies and market pressures.
Editorial Staff
1 min read
Pharmaceutical companies are currently facing significant challenges in launching new drugs in the European market. This situation is primarily driven by evolving pricing policies in the United States.
The delays in drug launches are raising concerns about the potential impact on healthcare systems in Europe, as timely access to new treatments may be hindered.
Key players in this scenario include Lilly and Biogen, both of which are reportedly adjusting their strategies in response to these pressures.